The First-Pass Hepatic Bottleneck

For decades, nutritional supplements relied upon direct L-Arginine administration to promote cardiovascular blood flow. However, pharmacokinetic studies repeatedly revealed that up to 70% of ingested oral L-arginine is degraded by intestinal and hepatic arginase enzymes before entering systemic circulation.

This intense enzymatic catabolism requires massive, unphysiological doses that frequently trigger gastrointestinal distress while producing only transient, erratic spikes in plasma nitric oxide levels.

Renal Biosynthesis of Systemic Arginine

L-Citrulline exhibits distinct pharmacokinetic characteristics. It does not act as a substrate for intestinal or hepatic arginase, allowing nearly 100% of an oral dose to cross into portal blood intact.

Once in the circulatory system, L-citrulline is transported to the kidneys, where renal tubular epithelial cells express argininosuccinate synthase and argininosuccinate lyase. These enzymes seamlessly convert citrulline into endogenous L-arginine, producing continuous plasma concentrations capable of saturating endothelial receptors over multi-hour horizons.

Integration into the Maxorin Protocol

Maxorin delivers pure free-form L-Citrulline paired with botanical polyphenols that preserve endothelial membrane integrity. By pairing citrulline with proanthocyanidins, the formula ensures that the synthesized nitric oxide is protected against premature free-radical degradation, supporting smooth microvascular compliance.